KRISHGEN Biosystems

KRIBIOLISA™ Semaglutide (Ozempic™) ELISA KIT
#KBI5030 
Introduction:
Semaglutide (trade name Ozempic) is a pharmaceutical drug in development by a Danish company Novo
Nordisk for the treatment of type 2 diabetes. It is marketed by the name Ozempic. As a glucagon-like peptide-1
receptor agonist, it lowers the blood sugar level by increasing the production of insulin. It was discovered in
2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. Clinical trials were
started in 2015, and phase 3 was completed in 2016. FDA approval was applied in December 2016, and in
October 2017 FDA Advisory Committee voted 16-0 in favor. It can be used as both injection-type or oral-type
drug.

Intended Use:
The KRIBIOLISA™ Semaglutide (Ozempic™) ELISA kit is used for estimation of Semaglutide in solutions and
human serum.
Principle:
The Semaglutide ELISA is a competitive immunoassay for the determination of Semaglutide. The anti-GLP-1
antibodies are coated on 96 well plate. A constant concentration of Biotinylated GLP-1 and varying
concentration of unlabeled Semaglutide or sample compete for binding to anti-GLP-1 antibodies. Captured
Biotinylated GLP-1 antibodies are subsequently bound by Streptavidin-HRP which produces a soluble colored
product after addition of TMB substrate. The enzyme reaction is stopped by dispensing of stop solution into the
wells. The optical density (OD) of the solution at 450 nm is inversely proportional to the amount of bound
Semaglutide molecule present in standards or samples.

More…